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Abstract 
Purpose: To report the short-term safety of dexamethasone implants to treat macular edema due to 
retinal vein occlusion (RVO), in eyes with treated glaucoma or ocular hypertension at baseline 
using an as-needed re-treatment regimen. 
Methods: Retrospective clinical database study from 2 centers using the same electronic medical 
record system. Extracted data included: intraocular pressure (IOP), visual acuity (VA), central 1mm 
retinal thickness (CRT) by optical coherence tomography, phakic status, number of injections, 
glaucoma treatment, and peri-operative complications. 
Results: Thirty-three eyes of 33 patients on IOP-lowering treatment for glaucoma or ocular 
hypertension (OHT) at baseline and mean IOP of 16mmHg at baseline received 1 to 4 (mean, 1.8; 
median, 1) dexamethasone implants over 18 months for RVO-related macular edema. Fourteen eyes 
(42%) had IOP of 21 mmHg, and three eyes (9%) had IOP of 35 mmHg at 1 or more visits 
during the study period. Nine of 14 eyes (64%) with raised IOP required additional topical 
treatment only for a mean (SE) period of 8.5 months (3.2), while the remaining 5 eyes (36%) 
required long-term additional IOP-lowering treatment for a mean (SE) of 16 months (1.44). Surgery 
for IOP lowering was not required in any eye. Mean VA (SE) improved from 44 (3) ETDRS letters 
at baseline to 47 letters (5) at 2 months (p=0.049), 48 (8) letters at 6 months and 46 (4) letters at 12 
months. Mean CRT (SE) improved from 530 (25) µm at baseline to 323 (27) µm at 2 months 
(p<0.001), 498 (76) µm at 6 months and 359 (25) µm at 12 months (p<0.001). 
Conclusion: The short-term IOP rise after intravitreal dexamethasone implant in eyes with 
glaucoma or ocular hypertension at baseline was acceptable and consistent with previous reports in 
patients without preexisting glaucoma. Treated OHT or glaucoma may not be a strict 
contraindication against the use of dexamethasone implant but close monitoring of IOP is required. 
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Introduction 
Retinal vein occlusion (RVO) is the second most common cause of vision loss due to retinal 
vascular disease, after diabetic retinopathy [1,2]. Until 2011, the standard of care for the treatment 
of macular edema from RVO was defined by the findings of the Branch Retinal Vein Occlusion 
Study and Central Retinal Vein Occlusion Study, that recommended grid laser photocoagulation for 
macular edema in non-ischemic branch RVO (BRVO) and observation of macular edema in central 
RVO (CRVO) [3-5]. Options for treatment of macular edema associated with RVO have, however, 
expanded in the past few years with the introduction of intravitreal corticosteroid treatments [6-8] 
and intravitreal treatment targeted against vascular endothelial growth factor (VEGF) [9-15].  
In the United Kingdom (UK), the sustained-release dexamethasone implant (Ozurdex, 
Allergan, Irvine, California, USA) was the first intravitreal treatment approved by National Institute 
for Health and Care Excellence (NICE) for treatment of macular edema due to RVO in July 2011, 
leading to its widespread adoption by the National Health Service (NHS). Ranibizumab treatment 
was approved by NICE for the same indications in May 2013 and aflibercept was approved for 
macular edema due to CRVO in February 2015 and for BRVO in September 2016. Accordingly, 
during the period of July 2011 to May 2013, dexamethasone implant was used nearly exclusively 
for treatment of RVO, apart from a few cases treated by bevacizumab as an off-license treatment 
[7]. 
Dexamethasone implant treatment for macular edema in RVO has been shown in clinical 
trials to be effective for treating RVO with an effect lasting up to 4 months after a single 
implantation [7,8,16]. Ease of insertion, an acceptable safety profile and prolonged duration of 
action support its use. The major safety concern has been its impact on IOP. Randomized controlled 
studies have shown that when intraocular pressure (IOP) rise occurs after dexamethasone implant 
injections is usually short-lived, moderate in severity, and readily managed with IOP-lowering 
therapy [7,8]. Nevertheless, patients using IOP-lowering medications were excluded from the phase 
3 studies of dexamethasone implant treatment in RVO [7,8]. In a ‘real–world’ clinical setting, 
approximately one third of the patients with RVO may have pre-existing glaucoma or OHT, and be 
using IOP-lowering medication [17]. This is not unexpected because these conditions are known 
risk factors for RVO [18].  
The purpose of this study was to audit ‘real-world’ data on the use of dexamethasone 
implants in patients with RVO and pre-existing glaucoma or OHT already on IOP-lowering 
treatment, a sub-group that has not been previously analyzed in any studies. 
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Methods 
 
Study population  
We retrospectively reviewed the electronic medical records (EMR) of 33 consecutive eyes 
(33 patients), who received one or more dexamethasone intravitreal implants for the treatment of 
macular edema due to RVO from 2 UK eye departments: Gloucestershire Hospitals NHS 
Foundation Trust and South Warwickshire NHS Foundation Trust, during the period from 1 
February 2012 to 30 September 2013. Collection of data was in the context of entirely electronic 
clinical data entry within an electronic medical record system (Medisoft Ophthalmology, Medisoft 
Ltd, Leeds, UK). All patients had been diagnosed with primary open angle glaucoma, confirmed 
with gonioscopy, or OHT and were using IOP-lowering treatment before initiating dexamethasone 
implant treatment and had at least 18 months of follow-up. For this study, patients were excluded if 
they were not on IOP-lowering treatment before the first dexamethasone implant, even if they were 
diagnosed with untreated OHT or were glaucoma suspects. Patients were also excluded if they had 
less than 18 months of follow-up following their first injection.  
All patient identifiers were removed to make data anonymous and the study was conducted 
in accordance with the declaration of Helsinki and the UK’s Data Protection Act of 1998. 
Anonymized database analyses of this type do not require ethical permission as they are viewed as 
audit for service evaluation [National Patient Safety Agency (UK). Defining research 2010. 
http://www.npsa.nhs.uk/nrls/research-and-evidence]. 
 
Clinical data 
Clinical and demographic data extracted from the EMR included: patients’ age at baseline, gender, 
type of RVO, laterality, previous ocular treatments, all known ocular and systemic co-morbidities, 
surgical details, number of injections, complications, visual acuity (VA), intraocular pressure (IOP), 
central retinal thickness (CRT) assessed by optical coherence tomography (OCT) at baseline, 2 
weeks then 4, 6, 8, 12 and 18 months months post-injection of the first intravitreal dexamethasone 
implant. Fluorescein angiography was performed at baseline only when there was uncertainty about 
the presence and severity of macular ischemia. 
 
Data sources/measurements 
As data were gathered from routine clinical settings, visual acuity was determined as the best VA 
with habitual VA correction or pinhole rather than best-corrected refracted VA at all time points. If 
more than one assessment of VA was made during that period, the VA demonstrating the greatest 
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improvement from baseline (peak effect) was used in the analysis. In patients where data were not 
available for a particular visit or had been lost to follow-up, no missing value substitutions were 
performed. Baseline central 1 mm subfield retinal thickness was defined as the last values measured 
on or before the day of the first dexamethasone implant injection. 
 
Statistical methods  
All data are expressed as the mean + standard error (SE) of the mean. Paired student's test was used 
to compare patient characteristics and OCT measurements between time points. The incidence rate 
of complications (IOP rise) and time-to-event analysis was performed using the Kaplan-Meier 
method. Spearman’s correlation test was used to investigate the correlation of the clinical 
characteristics. All statistical analyses were conducted using the SPSS statistical package (Statistical 
Package for Social Sciences version 21.0; SPSS, Inc., Chicago, IL). A P-value less than 0.05 was 
accepted as statistically significant. 
 
 
Results 
Thirty-three eyes of 33 patients who had been diagnosed with glaucoma or OHT and were 
on IOP-lowering treatment before first dexamethasone implant were included, 22 (67%) with 
CRVO and 11 (33%) with BRVO. The baseline characteristics of the study population are listed in 
Table 1. Overall, the mean age of the patients was 81.7 years. The macular edema associated with 
RVO diagnosis had a mean duration of 14.4 months (range: 0-55 months) at baseline. The mean 
time between diagnosis of RVO-related macular edema and the first dexamethasone implant 
treatment was 13.5 months in BRVO patients and 15.4 months in CRVO patients. This long 
duration of macular edema prior to treatment can be explained by the fact that our study included 
eyes that were diagnosed since 2009, prior to the approval of any pharmacological treatment 
(including dexamethasone implant) for RVO in the UK. Fluorescein angiography was performed in 
eight eyes (24%) at baseline. Five eyes (3 with CRVO and 2 with BRVO), which were included in 
the study (15%), had ischemia confirmed with fluorescein angiography. The majority of the eyes 
included in our study, 27 eyes (82%) had been diagnosed with glaucoma with the rest 6 eyes (18%) 
being diagnosed with OHT, all receiving IOP lowering substances. IOP was controlled with one 
topical substance in 17 eyes (51.5%), with the rest being on two topical substances and one eye 
being on triple therapy (Table 1). None of the study eyes had previous glaucoma surgery or 
received oral acetazolamide treatment at baseline. 
Other than for glaucoma and OHT, most of the eyes (76%) were treatment-naive and had 
not received intravitreal or laser treatment for RVO-associated complications before the first 
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dexamethasone implant. The remaining eyes, had other treatment before beginning dexamethasone 
implant treatment, where 5 eyes (15%) had intravitreal anti-VEGF treatment, 2 eyes (6%) had focal 
and/or panretinal laser photocoagulation in addition to anti-VEGF treatment, and one eye (3%) 
received sequential treatment with intravitreal triamcinolone treatment, intravitreal anti-VEGF 
treatment and and underwent pars plana vitrectomy surgery. None of the patients had a history of 
steroid-induced ocular hypertension. The period for data collection from the time of the first 
dexamethasone implant injection was at least 18 months to up to 24 months. The number of 
dexamethasone implants received over the follow period ranged from 1 to 4  (mean, 1.8; median, 1) 
and was similar for both BRVO and CRVO: 1.8 (0.1) in BRVO, and 1.8 (0.1) in CRVO \ Of 33 
study eyes, 11 (33%) were switched to anti-VEGF treatment after the first dexamethasone implant. 
Reasons for using anti-VEGF were: development of rubeosis / neovascular glaucoma in 4 eyes, no 
anatomical response of macular edema in 5 eyes, and significant increase in IOP (>35mmHg) in 2 
eyes (6% of study population). 
Among all eyes, 14 eyes (42%) had an IOP of 21 mmHg or higher at any time during the 
follow up period, while all eyes had IOP less than 21mmHg at baseline (mean, 16mmHg). A rise in 
IOP to 25mmHg or more was seen in 11 eyes (33%) following their first dexamethasone implant, 
and 3 eyes (9%) (3 eyes) had IOP of 35 mmHg or higher at 1 or more visits during the study period. 
Figure 1 demonstrates the timing of IOP rise. The rise in IOP was observed in the period from 2 
weeks to 2 months after first dexamethasone implant injection (p-value=0.006 and 0.001, at 2 
weeks and 2 months respectively). There was no correlation of IOP rise with the number of IOP-
lowering substances at baseline before first injection (Spearman’s correlation co-efficient 
rho=0.286; p-value=0.107). In eyes that received repeat intravitreal implants (16/33 eyes; 48.5 %), 
comparing the incidence of IOP rise after the first and subsequent treatments did not show a 
significant difference (figure 2). 
Raised IOP was medically treated in all the cases and none of our patients needed incisional 
surgery. Nine of 14 eyes (64.2%) with raised IOP were treated with topical therapy only, but 5 out 
of 14 (35.8% of eyes) required the addition of oral acetazolamide. Nine of 14 patients with raised 
IOP needed the additional topical treatment only while dexamethasone implant remained in vitreous 
for an average period (SE) of 8.5 months (3.2), and 5 of 14 (15% of eyes) required a more long-
term change in their IOP-lowering therapy over the entire mean follow up period (SE) of 15.75 
months (1.44) (figure 3). All eyes that had an IOP rise underwent gonioscopy to identify other 
factors that could cause the IOP elevation. Dexamethasone implant was the only factor explaining 
the IOP elevation, but four eyes with CRVO (12% of total study eyes) went on to develop 
neovascular glaucoma. These eyes with neovascular glaucoma were treated with a combination of 
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anti-hypertensive ocular agents, intravitreal bevacizumab injections and panretinal argon laser 
photocoagulation. 
Mean VA (SE) changed from 44 (3) ETDRS letters at baseline to 55 (4) ETDRS letters at 
week 2, to 47 (5) ETDRS letters at 2 months, to 45 (4) ETDRS letters at 4 months and to 48 (8) 
ETDRS letters at 6 months.  Mean VA (SE) was 46 (4) and 42 (5) ETDRS letters at 12 and 18 
months respectively (figure 4). While there was significant improvement in VA up to 2 months after 
first dexamethasone injection (p= 0.049), mean overall VA improvement at months 4, 6, 12 and 18 
from baseline did not show significance (p= 0.459, 0.660, 0.776 and 0.726). Mean CRT (SE) 
improved from 530 (25) µm at baseline to 283 (10) µm at week 2 (p<0.001), to 323 (27) µm at 2 
months (p<0.001) and to 445 (32) µm at 4 months (p=0.05). Mean CRT (SE) was 498 (76) µm at 6 
months (p=0.601), 359 (25) µm at 12 months (p<0.001) and 397 (34) µm at 18 months (p=0.003) 
(figure 5). CRT reduction was significant in the first four months after first dexamethasone 
injection, and remained statistically significant 12 and 18 months after the injection. Eyes with 
CRVO demonstrated increased CRT reduction compared to those with BRVO (figure 5), however, 
this difference was not found to be statistically significant at any time point (week 2, and month 2, 
4, 6, 12 and 18) after dexamethasone injection. 
Regarding other complications from dexamethasone implant, seven patients (7 out of 33 
eyes; 21%) underwent cataract surgery during the study period. No case of endophthalmitis, 
vitreous hemorrhage or retinal detachment was encountered. 
 
Discussion 
This study looked primarily at the short-term safety of dexamethasone implants when 
treating macular edema secondary to RVO, in eyes that had pre-existing glaucoma or ocular 
hypertension and were on IOP-lowering treatment at baseline. Our results demonstrate that the use 
of dexamethasone implant in this cohort of eyes is associated with an acceptable safety profile, 
specifically in relation to the frequency and magnitude of IOP rise. We observed an increase of IOP 
to >25mmHg in 33% of eyes and 42% of our study eyes required additional topical and/oral 
treatment for raised IOP, but none required surgery. Repeat dexamethasone implants were not 
associated with an increased risk of IOP rise compared to the first implant. 
The improvement of vision observed after treatment with dexamethasone implant in this 
study was inferior to that reported in the Phase 3, GENEVA studies of dexamethasone implant for 
macular edema after RVO [7,8]. In the Phase 3 studies, the cumulative response rate in achieving at 
least 3-line improvement in VA during the 6 months after the initial treatment with dexamethasone 
implant was 41% [7], while only 33% of our study eyes had a 3-line improvement in VA at week 4, 
with this effect wearing off and only 10% of our study eyes having a 3-line improvement in VA 
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three months after first injection. We would speculate that this could be due to our inclusion of eyes 
with poor vision at baseline and long duration of vein occlusion before starting treatment. Our re-
injection rate was also small with a mean number of approximately 2 implants over 18 months. 
The results observed in the current study regarding the IOP rise in patients with pre-existing 
ocular hypertension or glaucoma is not different to data from randomized pivotal studies 
[7,8,19,20], although these studies excluded eyes with pre-existing glaucoma or raised IOP. The 
MEAD study, a randomized, sham-controlled trial of dexamethasone intravitreal implant in patients 
with diabetic macular edema, provides the longest safety data on eyes treated with repeat implants 
with a follow up of 3 years and a mean number of 4.1 implants. Approximately one-third of eyes in 
the dexamethasone implant treatment groups in the MEAD study, had a clinically significant 
increase in IOP requiring treatment, no eye underwent removal of the implant to control IOP, and 
only 1 eye (0.3%) in each treatment group underwent glaucoma incisional surgery for steroid-
induced increases in IOP [19]. Similarly, 33% of our study eyes had a rise in IOP, and raised IOP 
was medically treated in all eyes. 
Regarding the effect of multiple treatments on IOP, we observed a rise in IOP in the period 
from 2 weeks to 2 months after the first dexamethasone implant injection, and in most eyes who had 
increased IOP, this happened after the second injection. This appears to be similar to eyes without 
glaucoma as demonstrated in MEAD study where mean IOP peaked at a similar level and returned 
to baseline levels by 6 months after each dexamethasone implant injection and neither the incidence 
of IOP adverse events nor the proportion of patients using IOP-lowering treatment increased after 
subsequent treatments in year 2 or 3 [19]. However, it is of note that only about half of our eyes 
(48.5%) received more than 1 injection.  
To our knowledge this the first study to analyse the safety and efficacy of dexamethasone 
implants in RVO in eyes with raised IOP on treatment before treatment of macular edema. Two 
other clinical database studies have included eyes with raised IOP at baseline but neither provided 
any details on IOP changes or visual acuity outcomes in these subgroups [17,21]. In one of these 
studies, almost one third of eyes (31.5%) had preexisting glaucoma or ocular hypertension, and 
24.2% were using IOP-lowering treatment before receiving their first dexamethasone implant 
treatment [17]. However, despite the inclusion of eyes with previous IOP rise or glaucoma, the rate 
of increases in IOP in their overall study population study was comparable to the MEAD Study 
with 32.8% of eyes treated with 2 dexamethasone implants having at least a 10-mmHg increase in 
IOP over 1-year and IOP-lowering treatment being required in 29.1% of patients. The ZERO study 
on reliability and safety of intravitreal dexamethasone implant injections from Germany was the 
second study to include patients with glaucoma at baseline treated by dexamethasone implant [21]. 
This study mentioned that in cases with known baseline glaucoma, intraocular pressure elevation 
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was not more frequent compared to non-glaucoma patients [21], however, the authors did not report 
any separate sub-group analysis of their glaucoma patients. 
Our study has limitations, which include the retrospective design, the lack of randomization 
and the relatively short follow-up period. Also, we based the outcome of this study on IOP control 
but did not analyze the impact of elevated IOP in our eyes. While monitoring of intraocular pressure 
in patients with pre-existing ocular hypertension or glaucoma is crucial, it is possible that the 
impairment of IOP control in this cohort may result in additional anatomical or functional damage 
that this study may not captured. Nevertheless, interpretation of functional (visual field testing) or 
morphological (retinal nerve fiber layer or optic nerve head analysis) tests in the context of RVO is 
challenging. Finally, it is worth noting that the mean number of re-treatment with dexamethasone 
implants in our study is small compared to other studies [22,23]. It is therefore possible that our 
cohort was undertreated and this itself may introduce bias to the results as further IOP rises in eyes 
with raised IOP or glaucoma may have been mitigated by administering fewer dexamethasone 
implants.  
In summary, the results of this study suggest that the clinical use of dexamethasone 
implants, has an acceptable safety profile regarding elevated IOP in patients with pre-existing 
glaucoma or OHT and that the rise in IOP in these eyes could be controlled with additional medical 
treatment. Our results suggest that similar to eyes that do not exhibit OHT or glaucoma, intravitreal 
dexamethasone deserves consideration in eyes with controlled OHT or glaucoma when anti-VEGF 
medications are contraindicated or not effective, but close monitoring is required.  
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Figure Legends 
 
Figure 1. Intraocular pressure changes after first injection of intravitreal dexamethasone for retinal 
vein occlusion. * p-value ≤ 0.001. 
Figure 2. Survival curve of time to IOP rise to >25mmHg after first injection of intravitreal 
dexamethasone for retinal vein occlusion related macular edema. In eyes that received repeat 
intravitreal implants, IOP rise is observed after the first injection, with no significant difference in 
incidence following subsequent treatments. 
Figure 3. Distribution of additional IOP lowering treatment administered to the patients during the 
study. 
Figure 4. Visual Acuity after first injection of intravitreal dexamethasone for retinal vein occlusion. 
BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion. * p-value ≤ 0.05. 
Figure 5. Central retinal thickness after first injection of intravitreal dexamethasone for retinal vein 
occlusion. BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion. * p-value ≤ 
0.05, ** p-value ≤ 0.001.  
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Table 1. Baseline characteristics of study population 
 
 
Baseline clinical characteristics of the study population 
Number of eyes (patients)  33 (33) 
Type of RVO (n) 
              
              CRVO 
              BRVO 
 
 
22  
11  
Age, years (mean, SE) 81.7 (1.0) 
Baseline VA, ETDRS letters (mean, SE) 44 (3) 
Baseline IOP, mmHg (mean, SE) 15 (0.52) 
Baseline CMT, μm (mean, SE) 530 (25.47) 
Duration of ME prior to treatment, 
months (mean, SE) 14.38 (3.9) 
Number of eyes with ocular 
comorbidities  
Primary open angle glaucoma 27 
Ocular Hypertension  
(all on medication) 6 
Number of lowering IOP substances  
one substance 17 
two substances 15 
three substances 1 
 
